FDA places partial hold on Biohaven's ion channel drug

FDA places partial clinical hold on Biohaven's epilepsy drug after rodent findings

The FDA imposed a partial clinical hold on Biohaven's experimental epilepsy drug BHV-7000 (opakalim), pausing new patient enrollment in trials following concerning findings in rodent studies. The hold was announced weeks after Biohaven sold rights to the therapy.